[Somatostatin receptor endoradiotherapy of neuroendocrine tumors: experience in Hungarian patients].
Identifieur interne : 001031 ( Main/Exploration ); précédent : 001030; suivant : 001032[Somatostatin receptor endoradiotherapy of neuroendocrine tumors: experience in Hungarian patients].
Auteurs : RBID : pubmed:21354955Descripteurs français
- Wicri :
- geographic : Hongrie.
English descriptors
- KwdEn :
- Adult, Aged, Female, Humans, Hungary, Indium Radioisotopes (therapeutic use), Lutetium (therapeutic use), Male, Middle Aged, Neuroendocrine Tumors (pathology), Neuroendocrine Tumors (radiotherapy), Radioisotopes (therapeutic use), Radiotherapy (adverse effects), Receptors, Somatostatin (metabolism), Receptors, Somatostatin (radiation effects), Remission Induction, Yttrium Radioisotopes (therapeutic use).
- MESH :
- chemical , metabolism : Receptors, Somatostatin.
- chemical , radiation effects : Receptors, Somatostatin.
- chemical , therapeutic use : Indium Radioisotopes, Lutetium, Radioisotopes, Yttrium Radioisotopes.
- geographic : Hungary.
- adverse effects : Radiotherapy.
- pathology : Neuroendocrine Tumors.
- radiotherapy : Neuroendocrine Tumors.
- Adult, Aged, Female, Humans, Male, Middle Aged, Remission Induction.
Abstract
Beside conventional therapies for the treatment of neuroendocrine tumors, a new therapeutical approach, peptide receptor radionuclide therapy has been developed recently. There are two important features which make this therapy feasible: somatostatin receptors are strongly over-expressed in most neuroendocrine tumors resulting in a high tumor-to-background ratio and internalization of the somatostatin-receptor complex in neuroendocrine cells. Due to these features, neuroendocrine tumors can be treated with radiolabelled somatostatin analogues. For peptide receptor radionuclide therapy, somatostatin analogues are conjugated to a chelator that can bind a radionuclide. The most frequently used radionuclides for neuroendocrine tumor treatment are the β-emitter Yttrium-90 (⁹⁰Y) and the β+γ emitter Lutetium-177 (¹⁷⁷Lu). Candidates for somatostatin receptor endoradiotherapy are patients with progressive, metastatic, somatostatin-receptor positive neuroendocrine tumors. Many patients have been successively treated with this approach: according to international results major remission can be achieved in 25% of the cases. Although this therapy is still unavailable in Hungary, Hungarian patients can be treated with somatostatin receptor endoradiotherapy with financial support from the National Health Fund in a co-operation with the University of Basel since 2005. During the past 5 years, 51 Hungarian patients have been treated with this therapy. This review briefly summarizes the theoretical background, indications, effectiveness and side effects of somatostatin receptor endoradiotherapy and the authors present the first data obtained from Hungarian patients.
DOI: 10.1556/OH.2011.29057
PubMed: 21354955
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">[Somatostatin receptor endoradiotherapy of neuroendocrine tumors: experience in Hungarian patients].</title><author><name sortKey="Reismann, Peter" uniqKey="Reismann P">Péter Reismann</name><affiliation wicri:level="3"><nlm:affiliation>Semmelweis Egyetem, Általános Orvostudományi Kar, II. Belgyógyászati Klinika, Budapest. reismann@freestart.hu</nlm:affiliation><country>Hongrie</country><placeName><settlement type="city">Budapest</settlement><region nuts="2">Hongrie centrale</region></placeName><wicri:orgArea>Semmelweis Egyetem, Általános Orvostudományi Kar, II. Belgyógyászati Klinika</wicri:orgArea></affiliation></author><author><name sortKey="Kender, Zolt N" uniqKey="Kender Z">Zoltán Kender</name></author><author><name sortKey="Dabasi, Gabriella" uniqKey="Dabasi G">Gabriella Dabasi</name></author><author><name sortKey="Sreter, L Dia" uniqKey="Sreter L">Lídia Sréter</name></author><author><name sortKey="R Cz, K Roly" uniqKey="R Cz K">Károly Rácz</name></author><author><name sortKey="Igaz, Peter" uniqKey="Igaz P">Péter Igaz</name></author></titleStmt><publicationStmt><date when="2011">2011</date><idno type="doi">10.1556/OH.2011.29057</idno><idno type="RBID">pubmed:21354955</idno><idno type="pmid">21354955</idno><idno type="wicri:Area/Main/Corpus">001556</idno><idno type="wicri:Area/Main/Curation">001556</idno><idno type="wicri:Area/Main/Exploration">001031</idno></publicationStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Female</term><term>Humans</term><term>Hungary</term><term>Indium Radioisotopes (therapeutic use)</term><term>Lutetium (therapeutic use)</term><term>Male</term><term>Middle Aged</term><term>Neuroendocrine Tumors (pathology)</term><term>Neuroendocrine Tumors (radiotherapy)</term><term>Radioisotopes (therapeutic use)</term><term>Radiotherapy (adverse effects)</term><term>Receptors, Somatostatin (metabolism)</term><term>Receptors, Somatostatin (radiation effects)</term><term>Remission Induction</term><term>Yttrium Radioisotopes (therapeutic use)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Receptors, Somatostatin</term></keywords><keywords scheme="MESH" type="chemical" qualifier="radiation effects" xml:lang="en"><term>Receptors, Somatostatin</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Indium Radioisotopes</term><term>Lutetium</term><term>Radioisotopes</term><term>Yttrium Radioisotopes</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>Hungary</term></keywords><keywords scheme="MESH" qualifier="adverse effects" xml:lang="en"><term>Radiotherapy</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Neuroendocrine Tumors</term></keywords><keywords scheme="MESH" qualifier="radiotherapy" xml:lang="en"><term>Neuroendocrine Tumors</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Remission Induction</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Hongrie</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Beside conventional therapies for the treatment of neuroendocrine tumors, a new therapeutical approach, peptide receptor radionuclide therapy has been developed recently. There are two important features which make this therapy feasible: somatostatin receptors are strongly over-expressed in most neuroendocrine tumors resulting in a high tumor-to-background ratio and internalization of the somatostatin-receptor complex in neuroendocrine cells. Due to these features, neuroendocrine tumors can be treated with radiolabelled somatostatin analogues. For peptide receptor radionuclide therapy, somatostatin analogues are conjugated to a chelator that can bind a radionuclide. The most frequently used radionuclides for neuroendocrine tumor treatment are the β-emitter Yttrium-90 (⁹⁰Y) and the β+γ emitter Lutetium-177 (¹⁷⁷Lu). Candidates for somatostatin receptor endoradiotherapy are patients with progressive, metastatic, somatostatin-receptor positive neuroendocrine tumors. Many patients have been successively treated with this approach: according to international results major remission can be achieved in 25% of the cases. Although this therapy is still unavailable in Hungary, Hungarian patients can be treated with somatostatin receptor endoradiotherapy with financial support from the National Health Fund in a co-operation with the University of Basel since 2005. During the past 5 years, 51 Hungarian patients have been treated with this therapy. This review briefly summarizes the theoretical background, indications, effectiveness and side effects of somatostatin receptor endoradiotherapy and the authors present the first data obtained from Hungarian patients.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">21354955</PMID><DateCreated><Year>2011</Year><Month>02</Month><Day>28</Day></DateCreated><DateCompleted><Year>2011</Year><Month>04</Month><Day>08</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0030-6002</ISSN><JournalIssue CitedMedium="Print"><Volume>152</Volume><Issue>10</Issue><PubDate><Year>2011</Year><Month>Mar</Month><Day>6</Day></PubDate></JournalIssue><Title>Orvosi hetilap</Title><ISOAbbreviation>Orv Hetil</ISOAbbreviation></Journal><ArticleTitle>[Somatostatin receptor endoradiotherapy of neuroendocrine tumors: experience in Hungarian patients].</ArticleTitle><Pagination><MedlinePgn>392-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1556/OH.2011.29057</ELocationID><Abstract><AbstractText>Beside conventional therapies for the treatment of neuroendocrine tumors, a new therapeutical approach, peptide receptor radionuclide therapy has been developed recently. There are two important features which make this therapy feasible: somatostatin receptors are strongly over-expressed in most neuroendocrine tumors resulting in a high tumor-to-background ratio and internalization of the somatostatin-receptor complex in neuroendocrine cells. Due to these features, neuroendocrine tumors can be treated with radiolabelled somatostatin analogues. For peptide receptor radionuclide therapy, somatostatin analogues are conjugated to a chelator that can bind a radionuclide. The most frequently used radionuclides for neuroendocrine tumor treatment are the β-emitter Yttrium-90 (⁹⁰Y) and the β+γ emitter Lutetium-177 (¹⁷⁷Lu). Candidates for somatostatin receptor endoradiotherapy are patients with progressive, metastatic, somatostatin-receptor positive neuroendocrine tumors. Many patients have been successively treated with this approach: according to international results major remission can be achieved in 25% of the cases. Although this therapy is still unavailable in Hungary, Hungarian patients can be treated with somatostatin receptor endoradiotherapy with financial support from the National Health Fund in a co-operation with the University of Basel since 2005. During the past 5 years, 51 Hungarian patients have been treated with this therapy. This review briefly summarizes the theoretical background, indications, effectiveness and side effects of somatostatin receptor endoradiotherapy and the authors present the first data obtained from Hungarian patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Reismann</LastName><ForeName>Péter</ForeName><Initials>P</Initials><Affiliation>Semmelweis Egyetem, Általános Orvostudományi Kar, II. Belgyógyászati Klinika, Budapest. reismann@freestart.hu</Affiliation></Author><Author ValidYN="Y"><LastName>Kender</LastName><ForeName>Zoltán</ForeName><Initials>Z</Initials></Author><Author ValidYN="Y"><LastName>Dabasi</LastName><ForeName>Gabriella</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Sréter</LastName><ForeName>Lídia</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Rácz</LastName><ForeName>Károly</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Igaz</LastName><ForeName>Péter</ForeName><Initials>P</Initials></Author></AuthorList><Language>hun</Language><PublicationTypeList><PublicationType>English Abstract</PublicationType><PublicationType>Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Neuroendokrin daganatok szomatosztatinreceptor-endoradioterápiája: hazai betegeken szerzett tapasztalatok.</VernacularTitle></Article><MedlineJournalInfo><Country>Hungary</Country><MedlineTA>Orv Hetil</MedlineTA><NlmUniqueID>0376412</NlmUniqueID><ISSNLinking>0030-6002</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Indium Radioisotopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Radioisotopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Receptors, Somatostatin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Yttrium Radioisotopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>5H0DOZ21UJ</RegistryNumber><NameOfSubstance>Lutetium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" Type="Geographic">Hungary</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Indium Radioisotopes</DescriptorName><QualifierName MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Lutetium</DescriptorName><QualifierName MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Neuroendocrine Tumors</DescriptorName><QualifierName MajorTopicYN="N">pathology</QualifierName><QualifierName MajorTopicYN="Y">radiotherapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Radioisotopes</DescriptorName><QualifierName MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Radiotherapy</DescriptorName><QualifierName MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Receptors, Somatostatin</DescriptorName><QualifierName MajorTopicYN="N">metabolism</QualifierName><QualifierName MajorTopicYN="Y">radiation effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Remission Induction</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Yttrium Radioisotopes</DescriptorName><QualifierName MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>3</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>3</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>4</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pii">MRP844L78564UV18</ArticleId><ArticleId IdType="doi">10.1556/OH.2011.29057</ArticleId><ArticleId IdType="pubmed">21354955</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=IndiumV2/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001031 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001031 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= *** parameter Area/wikiCode missing ***
|area= IndiumV2
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:21354955
|texte= [Somatostatin receptor endoradiotherapy of neuroendocrine tumors: experience in Hungarian patients].
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:21354955" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a IndiumV2
| This area was generated with Dilib version V0.5.76. |  |